摘要
急性冠脉综合征是威胁人类健康的重大心血管疾病,但由于多数抗血小板药物经肾脏代谢,因此,慢性肾脏病合并急性冠脉综合征患者的抗血小板药物选择成为长期研究的热点。替格瑞洛由于特殊的药代动力学和药效学特征,在诸多临床研究中相比氯吡格雷体现出极大的优越性,能显著降低急性冠脉综合征合并慢性肾脏病患者的主要不良心血管事件发生率。现结合近年来国内外多项研究,对替格瑞洛在急性冠脉综合征合并慢性肾脏病中的临床研究进展做一综述。
Acute coronary syndrome(ACS)is a major cardiovascular disease with tremendous impact on human health.However,most antiplatelet drugs are metabolized by the kidneys,thus the selection of antiplatelet drugs in patients with chronic kidney disease(CKD)and ACS had become a hot research for a long time.Due to the special pharmacokinetic and pharmacodynamic characteristics,ticagrelor showed great advantages in many studies compared with clopidogrel,and it can significantly reduce the incidence of major adverse cardiovascular events in patients with ACS and CKD.Based on the recent studies all over the world,we reviewed the advance of ticagrelor for ACS with CKD.
作者
周小琳
何泉
ZHOU Xiaolin;HE Quan(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《心血管病学进展》
CAS
2019年第5期718-722,共5页
Advances in Cardiovascular Diseases
基金
国家重点研发计划(2018YFC1311404)
关键词
替格瑞洛
急性冠脉综合征
慢性肾脏病
Ticagrelor
Acute coronary syndrome
Chronic kidney disease
作者简介
通讯作者:何泉,E-mail:hequan822@aliyun.com。
